144 related articles for article (PubMed ID: 26678979)
1. Association of Cancer Stem Cell Markers With Aggressive Tumor Features in Papillary Thyroid Carcinoma.
Lin Z; Lu X; Li W; Sun M; Peng M; Yang H; Chen L; Zhang C; Cai L; Li Y
Cancer Control; 2015 Oct; 22(4):508-14. PubMed ID: 26678979
[TBL] [Abstract][Full Text] [Related]
2. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
Han SA; Jang JH; Won KY; Lim SJ; Song JY
Pathol Res Pract; 2017 Aug; 213(8):956-963. PubMed ID: 28687160
[TBL] [Abstract][Full Text] [Related]
4. Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers.
Hardin H; Montemayor-Garcia C; Lloyd RV
Hum Pathol; 2013 Sep; 44(9):1707-13. PubMed ID: 23528862
[TBL] [Abstract][Full Text] [Related]
5. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma.
Liu J; Brown RE
Int J Clin Exp Pathol; 2010 Oct; 3(8):755-62. PubMed ID: 21151388
[TBL] [Abstract][Full Text] [Related]
8. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
9. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
Balta AZ; Filiz AI; Kurt Y; Sucullu I; Yucel E; Akin ML
Med Oncol; 2012 Jun; 29(2):734-41. PubMed ID: 21547408
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
12. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
14. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
15. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.
Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
[TBL] [Abstract][Full Text] [Related]
16. Multicompartment metabolism in papillary thyroid cancer.
Curry JM; Tassone P; Cotzia P; Sprandio J; Luginbuhl A; Cognetti DM; Mollaee M; Domingo M; Pribitkin EA; Keane WM; Zhan TT; Birbe R; Tuluc M; Martinez-Outschoorn U
Laryngoscope; 2016 Oct; 126(10):2410-2418. PubMed ID: 26666958
[TBL] [Abstract][Full Text] [Related]
17. Detection of thyroid cancer stem cells in papillary thyroid carcinoma.
Ahn SH; Henderson YC; Williams MD; Lai SY; Clayman GL
J Clin Endocrinol Metab; 2014 Feb; 99(2):536-44. PubMed ID: 24302752
[TBL] [Abstract][Full Text] [Related]
18. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
19. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer.
Beck AC; Rajan A; Landers S; Kelley S; Bellizzi AM; Lal G; Sugg SL; Howe JR; Chan CH; Weigel RJ
Surgery; 2022 Jan; 171(1):245-251. PubMed ID: 34362588
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
